Loading…
Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat
Background Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510). Experimental Design T...
Saved in:
| Published in: | Head & neck 2023-02, Vol.45 (2), p.391-397 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c4432-2c9c1ef750f422bbea804dacdc467f3b40d1cad103f55001d3c790f7e3df47a63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c4432-2c9c1ef750f422bbea804dacdc467f3b40d1cad103f55001d3c790f7e3df47a63 |
| container_end_page | 397 |
| container_issue | 2 |
| container_start_page | 391 |
| container_title | Head & neck |
| container_volume | 45 |
| creator | Pan, Cassie Wu, Qian “Vicky” Voutsinas, Jenna Houlton, Jeffrey J. Barber, Brittany Futran, Neal Laramore, George E. Liao, Jay J. Parvathaneni, Upendra Martins, Renato G. Fromm, Jonathan R. Rodriguez, Cristina P. |
| description | Background
Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510).
Experimental Design
Twenty‐five HN and 25 SGCs were treated with pembrolizumab and vorinostat. Baseline peripheral blood was available in 21 HN and 20 SGCs and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS), and progression‐free survival (PFS).
Results
Higher pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and neutrophils, as well as lower pretreatment lymphocytes and T helper cells correlated with worse OS and PFS. Higher NLR further predicted increased rates of G ≥ 3AEs. No correlations with ORR were observed.
Conclusions
In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities. |
| doi_str_mv | 10.1002/hed.27252 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9812876</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2759914805</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4432-2c9c1ef750f422bbea804dacdc467f3b40d1cad103f55001d3c790f7e3df47a63</originalsourceid><addsrcrecordid>eNp1kc9u1DAQhyMEoqVw4AWQJU4c0vpf1psLEmoLRargAmfLsSeN2yQTbGer8Hg8Gd5NqeDAaUbyN59H8yuK14yeMkr5WQfulCte8SfFMaO1KqmQ6um-l6IUVMmj4kWMt5RSsZH8eXGUC-N0I4-LX19gTgGnzvckIemXYerQLglIMMkjMaMjEwQ_dRBMT5oe0ZHG42DCHYRILIYAvcn8vU8diXPY-V0GcU4WB4ikmRMZMZEAccIxAjEDjjekA-MO8hHs3aGJps-TYSHWjBYCSQGy1q3eCYYmYO9_zoNpDvgOgx8xJpNeFs9a00d49VBPiu8fL7-dX5XXXz99Pv9wXVopBS-5rS2DVlW0lZw3DZgtlc5YZ-VGtaKR1DFrHKOirSpKmRNW1bRVIFwrldmIk-L96p3mZgBnYUz5JHoKPh9j0Wi8_vdl9J2-wZ2ut4xv1V7w9kEQ8McMMelbnMOYd9ZcVXXN5JZWmXq3UjZgjAHaxx8Y1fu4dY5bH-LO7Ju_V3ok_-SbgbMVuPc9LP836avLi1X5GzUgu-g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2759914805</pqid></control><display><type>article</type><title>Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat</title><source>Wiley-Blackwell Read & Publish Collection</source><creator>Pan, Cassie ; Wu, Qian “Vicky” ; Voutsinas, Jenna ; Houlton, Jeffrey J. ; Barber, Brittany ; Futran, Neal ; Laramore, George E. ; Liao, Jay J. ; Parvathaneni, Upendra ; Martins, Renato G. ; Fromm, Jonathan R. ; Rodriguez, Cristina P.</creator><creatorcontrib>Pan, Cassie ; Wu, Qian “Vicky” ; Voutsinas, Jenna ; Houlton, Jeffrey J. ; Barber, Brittany ; Futran, Neal ; Laramore, George E. ; Liao, Jay J. ; Parvathaneni, Upendra ; Martins, Renato G. ; Fromm, Jonathan R. ; Rodriguez, Cristina P.</creatorcontrib><description>Background
Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510).
Experimental Design
Twenty‐five HN and 25 SGCs were treated with pembrolizumab and vorinostat. Baseline peripheral blood was available in 21 HN and 20 SGCs and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS), and progression‐free survival (PFS).
Results
Higher pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and neutrophils, as well as lower pretreatment lymphocytes and T helper cells correlated with worse OS and PFS. Higher NLR further predicted increased rates of G ≥ 3AEs. No correlations with ORR were observed.
Conclusions
In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities.</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.27252</identifier><identifier>PMID: 36412064</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Biomarkers ; Head & neck cancer ; head and neck cancer ; Head and neck carcinoma ; Head and Neck Neoplasms - drug therapy ; Helper cells ; Humans ; Immunotherapy ; Leukocytes (neutrophilic) ; Lymphocytes ; Lymphocytes - pathology ; Metastases ; Monoclonal antibodies ; Neoplasm Recurrence, Local - pathology ; Neutrophils - pathology ; Oral cancer ; Pembrolizumab ; Peripheral blood ; peripheral blood biomarkers ; Prognosis ; Salivary gland ; salivary gland cancer ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck ; Targeted cancer therapy ; Vorinostat</subject><ispartof>Head & neck, 2023-02, Vol.45 (2), p.391-397</ispartof><rights>2022 Wiley Periodicals LLC.</rights><rights>2023 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4432-2c9c1ef750f422bbea804dacdc467f3b40d1cad103f55001d3c790f7e3df47a63</citedby><cites>FETCH-LOGICAL-c4432-2c9c1ef750f422bbea804dacdc467f3b40d1cad103f55001d3c790f7e3df47a63</cites><orcidid>0000-0002-9202-4813 ; 0000-0003-2423-658X ; 0000-0003-2776-4679</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36412064$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Cassie</creatorcontrib><creatorcontrib>Wu, Qian “Vicky”</creatorcontrib><creatorcontrib>Voutsinas, Jenna</creatorcontrib><creatorcontrib>Houlton, Jeffrey J.</creatorcontrib><creatorcontrib>Barber, Brittany</creatorcontrib><creatorcontrib>Futran, Neal</creatorcontrib><creatorcontrib>Laramore, George E.</creatorcontrib><creatorcontrib>Liao, Jay J.</creatorcontrib><creatorcontrib>Parvathaneni, Upendra</creatorcontrib><creatorcontrib>Martins, Renato G.</creatorcontrib><creatorcontrib>Fromm, Jonathan R.</creatorcontrib><creatorcontrib>Rodriguez, Cristina P.</creatorcontrib><title>Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510).
Experimental Design
Twenty‐five HN and 25 SGCs were treated with pembrolizumab and vorinostat. Baseline peripheral blood was available in 21 HN and 20 SGCs and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS), and progression‐free survival (PFS).
Results
Higher pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and neutrophils, as well as lower pretreatment lymphocytes and T helper cells correlated with worse OS and PFS. Higher NLR further predicted increased rates of G ≥ 3AEs. No correlations with ORR were observed.
Conclusions
In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities.</description><subject>Biomarkers</subject><subject>Head & neck cancer</subject><subject>head and neck cancer</subject><subject>Head and neck carcinoma</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Helper cells</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes</subject><subject>Lymphocytes - pathology</subject><subject>Metastases</subject><subject>Monoclonal antibodies</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neutrophils - pathology</subject><subject>Oral cancer</subject><subject>Pembrolizumab</subject><subject>Peripheral blood</subject><subject>peripheral blood biomarkers</subject><subject>Prognosis</subject><subject>Salivary gland</subject><subject>salivary gland cancer</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck</subject><subject>Targeted cancer therapy</subject><subject>Vorinostat</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp1kc9u1DAQhyMEoqVw4AWQJU4c0vpf1psLEmoLRargAmfLsSeN2yQTbGer8Hg8Gd5NqeDAaUbyN59H8yuK14yeMkr5WQfulCte8SfFMaO1KqmQ6um-l6IUVMmj4kWMt5RSsZH8eXGUC-N0I4-LX19gTgGnzvckIemXYerQLglIMMkjMaMjEwQ_dRBMT5oe0ZHG42DCHYRILIYAvcn8vU8diXPY-V0GcU4WB4ikmRMZMZEAccIxAjEDjjekA-MO8hHs3aGJps-TYSHWjBYCSQGy1q3eCYYmYO9_zoNpDvgOgx8xJpNeFs9a00d49VBPiu8fL7-dX5XXXz99Pv9wXVopBS-5rS2DVlW0lZw3DZgtlc5YZ-VGtaKR1DFrHKOirSpKmRNW1bRVIFwrldmIk-L96p3mZgBnYUz5JHoKPh9j0Wi8_vdl9J2-wZ2ut4xv1V7w9kEQ8McMMelbnMOYd9ZcVXXN5JZWmXq3UjZgjAHaxx8Y1fu4dY5bH-LO7Ju_V3ok_-SbgbMVuPc9LP836avLi1X5GzUgu-g</recordid><startdate>202302</startdate><enddate>202302</enddate><creator>Pan, Cassie</creator><creator>Wu, Qian “Vicky”</creator><creator>Voutsinas, Jenna</creator><creator>Houlton, Jeffrey J.</creator><creator>Barber, Brittany</creator><creator>Futran, Neal</creator><creator>Laramore, George E.</creator><creator>Liao, Jay J.</creator><creator>Parvathaneni, Upendra</creator><creator>Martins, Renato G.</creator><creator>Fromm, Jonathan R.</creator><creator>Rodriguez, Cristina P.</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9202-4813</orcidid><orcidid>https://orcid.org/0000-0003-2423-658X</orcidid><orcidid>https://orcid.org/0000-0003-2776-4679</orcidid></search><sort><creationdate>202302</creationdate><title>Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat</title><author>Pan, Cassie ; Wu, Qian “Vicky” ; Voutsinas, Jenna ; Houlton, Jeffrey J. ; Barber, Brittany ; Futran, Neal ; Laramore, George E. ; Liao, Jay J. ; Parvathaneni, Upendra ; Martins, Renato G. ; Fromm, Jonathan R. ; Rodriguez, Cristina P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4432-2c9c1ef750f422bbea804dacdc467f3b40d1cad103f55001d3c790f7e3df47a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Head & neck cancer</topic><topic>head and neck cancer</topic><topic>Head and neck carcinoma</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Helper cells</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes</topic><topic>Lymphocytes - pathology</topic><topic>Metastases</topic><topic>Monoclonal antibodies</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neutrophils - pathology</topic><topic>Oral cancer</topic><topic>Pembrolizumab</topic><topic>Peripheral blood</topic><topic>peripheral blood biomarkers</topic><topic>Prognosis</topic><topic>Salivary gland</topic><topic>salivary gland cancer</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck</topic><topic>Targeted cancer therapy</topic><topic>Vorinostat</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Cassie</creatorcontrib><creatorcontrib>Wu, Qian “Vicky”</creatorcontrib><creatorcontrib>Voutsinas, Jenna</creatorcontrib><creatorcontrib>Houlton, Jeffrey J.</creatorcontrib><creatorcontrib>Barber, Brittany</creatorcontrib><creatorcontrib>Futran, Neal</creatorcontrib><creatorcontrib>Laramore, George E.</creatorcontrib><creatorcontrib>Liao, Jay J.</creatorcontrib><creatorcontrib>Parvathaneni, Upendra</creatorcontrib><creatorcontrib>Martins, Renato G.</creatorcontrib><creatorcontrib>Fromm, Jonathan R.</creatorcontrib><creatorcontrib>Rodriguez, Cristina P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Cassie</au><au>Wu, Qian “Vicky”</au><au>Voutsinas, Jenna</au><au>Houlton, Jeffrey J.</au><au>Barber, Brittany</au><au>Futran, Neal</au><au>Laramore, George E.</au><au>Liao, Jay J.</au><au>Parvathaneni, Upendra</au><au>Martins, Renato G.</au><au>Fromm, Jonathan R.</au><au>Rodriguez, Cristina P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2023-02</date><risdate>2023</risdate><volume>45</volume><issue>2</issue><spage>391</spage><epage>397</epage><pages>391-397</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><abstract>Background
Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510).
Experimental Design
Twenty‐five HN and 25 SGCs were treated with pembrolizumab and vorinostat. Baseline peripheral blood was available in 21 HN and 20 SGCs and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS), and progression‐free survival (PFS).
Results
Higher pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and neutrophils, as well as lower pretreatment lymphocytes and T helper cells correlated with worse OS and PFS. Higher NLR further predicted increased rates of G ≥ 3AEs. No correlations with ORR were observed.
Conclusions
In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities.</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>36412064</pmid><doi>10.1002/hed.27252</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-9202-4813</orcidid><orcidid>https://orcid.org/0000-0003-2423-658X</orcidid><orcidid>https://orcid.org/0000-0003-2776-4679</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2023-02, Vol.45 (2), p.391-397 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9812876 |
| source | Wiley-Blackwell Read & Publish Collection |
| subjects | Biomarkers Head & neck cancer head and neck cancer Head and neck carcinoma Head and Neck Neoplasms - drug therapy Helper cells Humans Immunotherapy Leukocytes (neutrophilic) Lymphocytes Lymphocytes - pathology Metastases Monoclonal antibodies Neoplasm Recurrence, Local - pathology Neutrophils - pathology Oral cancer Pembrolizumab Peripheral blood peripheral blood biomarkers Prognosis Salivary gland salivary gland cancer Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck Targeted cancer therapy Vorinostat |
| title | Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T23%3A52%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Neutrophil%20to%20lymphocyte%20ratio%20and%20peripheral%20blood%20biomarkers%20correlate%20with%20survival%20outcomes%20but%20not%20response%20among%20head%20and%20neck%20and%20salivary%20cancer%20treated%20with%20pembrolizumab%20and%20vorinostat&rft.jtitle=Head%20&%20neck&rft.au=Pan,%20Cassie&rft.date=2023-02&rft.volume=45&rft.issue=2&rft.spage=391&rft.epage=397&rft.pages=391-397&rft.issn=1043-3074&rft.eissn=1097-0347&rft_id=info:doi/10.1002/hed.27252&rft_dat=%3Cproquest_pubme%3E2759914805%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4432-2c9c1ef750f422bbea804dacdc467f3b40d1cad103f55001d3c790f7e3df47a63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2759914805&rft_id=info:pmid/36412064&rfr_iscdi=true |